NeuroSense Therapeutics Ltd. Adjustments For Finance Costs
NeuroSense Therapeutics Ltd. (NRSN) reported Adjustments For Finance Costs of $1.66 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForFinanceCosts · last filed 2024-04-04
| Period end | Adjustments For Finance Costs 12 month |
|---|---|
| 2023-12-31 | $1.66M 20-F · filed 2024-04-04 |